Eupraxia Pharmaceuticals (EPRX) Net Income towards Common Stockholders (2023 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 4 years of Net Income towards Common Stockholders data on file, last reported at -$12.7 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 87.0% year-over-year to -$12.7 million in Q1 2026; TTM through Mar 2026 was -$27.8 million, a 47.55% decrease from a year earlier, with the FY2025 full-year figure at -$38.6 million, down 49.96% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$12.7 million, down from -$6.4 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for EPRX reached as high as -$4.0 million in Q1 2023 and fell as low as -$12.7 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$7.1 million across 4 years, with a median of -$6.3 million in 2024.
• Across the five-year window, Net Income towards Common Stockholders jumped 36.21% in 2024 and slumped 87.0% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$4.9 million in 2023, then fell by 22.37% to -$6.0 million in 2024, then fell by 6.31% to -$6.4 million in 2025, then plunged by 98.68% to -$12.7 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$12.7 million in Q1 2026, -$6.4 million in Q3 2025, and -$8.7 million in Q2 2025.